3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
193
Recurrence
48
Neoplasms, Plasma Cell
19
Neoplasms
13
Immunoglobulin Light-chain Amyloidosis
10
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Non-Hodgkin
5
Myeloproliferative Disorders
4
Lymphoma, B-Cell
4
Hematologic Diseases
4
Amyloidosis
4
Waldenstrom Macroglobulinemia
3
Sarcoma, Kaposi
3
Renal Insufficiency
3
Primary Myelofibrosis
3
Polycythemia Vera
3
Leukemia, Myeloid, Acute
3
Hematologic Neoplasms
3
Burkitt Lymphoma
3
Blood Protein Disorders
3
Plasmacytoma
2
Paraproteinemias
2
Neoplasms by Histologic Type
2
Disease Progression
2
Chromosome 17 deletion
2
Central Nervous System Neoplasms
2
Acquired Immunodeficiency Syndrome
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Interventions
venetoclax
6
fludarabine phosphate
5
Dexamethasone
4
ibrutinib
3
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
pomalidomide
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Mycophenolic Acid
2
pirtobrutinib
1
pembrolizumab
1
obinutuzumab
1
ixazomib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
carmustine, poliferprosan 20 drug combination
1
auricularum
1
acalabrutinib
1
Sirolimus
1
RG7388
1
Nivolumab
1
Maintenance
1
Etoposide
1
Cytarabine
1
Cyclosporins
1
Cyclosporine
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Chromosome 17 deletion
×
pomalidomide
×
Clear all
NCT01745640
2026-02-05
IFM2010-02
University Hospital, Lille
Phase 2
Completed
63 enrolled
NCT04124497
2025-08-08
DPd
Fondazione EMN Italy Onlus
Phase 2
Active not recruiting
45 enrolled